 enhanc product neutrophil-activ rheumatoid arthriti product neutrophil-activ peptid nap mononuclear phagocyt patient RA control subject variou condit mononuclear cell bone marrow bmmc pbmc synovi fluid sfmc absenc presenc escherichia coli lp differ interleukin interferon-gamma zymosan immun complex neutrophil-stimul activ cultur medium neutral antiserum human recombin activ unstimul mononuclear cell control individu bmmc RA patient product low stimul lp contrast spontan product pbmc much sfmc RA patient instanc yield stimul cultur addit lp rheumatoid factor-contain immun complex zymosan effect product gm-csf tumor necrosi factor tnf less potent inhibitori effect ifn-gamma spontan releas sfmc lps-induc RA pbmc inhibit glucocorticoid product dexamethason phagocytosis-stimul pbmc inhibit sfmc joint intraarticular administr betamethason contrast cyclooxygenas inhibitor indomethacin yield pbmc cultur